Combining peptide TNIIIA2 with all-
ATRA
N-Myc
Neuroblastoma
differentiation therapy
integrin
mycn
proto-oncogene
retinoic acid
tenascin-C
ubiquitin-proteasome system
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
12
2018
accepted:
07
01
2019
entrez:
26
3
2019
pubmed:
25
3
2019
medline:
25
3
2019
Statut:
epublish
Résumé
Neuroblastoma is one of the common solid tumors of childhood. Nearly half of neuroblastoma patients are classified into the high-risk group, and their 5-year event-free survival (EFS) rates remain unsatisfactory in the range of 30-40%. High-risk neuroblastoma is characterized by amplification of the MYCN gene and excessive expression of its protein product, N-Myc. Because N-Myc is a transcription factor for various pro-proliferative proteins, the excessive expression causes aberrant or blocked neuronal differentiation during development of sympathetic nervous system, which is a central aspect of neuroblastoma genesis. The current main treatment for high-risk neuroblastoma is intensive chemotherapy using anti-cancer drugs that induce apoptosis in tumor cells, but intensive chemotherapy has another serious risk of long-lasting side effects, so-called "late effects", that occur many years after chemotherapy has ended. As a solution for such situation, differentiation therapy has been expected as a mild chemotherapy with a low risk of late effects, and an application of retinoic acid (RA) and its derivatives as treatment for high-risk neuroblastoma has long been attempted. However, the clinical outcome has not been sufficient with the use of retinoids, including all-
Types de publication
Journal Article
Langues
eng
Pagination
434-448Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
None.
Références
Science. 1999 Aug 13;285(5430):1028-32
pubmed: 10446041
N Engl J Med. 1999 Oct 14;341(16):1165-73
pubmed: 10519894
Nature. 2000 Apr 13;404(6779):770-4
pubmed: 10783891
Pharmacol Ther. 2001 May-Jun;90(2-3):105-56
pubmed: 11578655
Mol Cell Biol. 2002 Mar;22(5):1352-9
pubmed: 11839802
Int J Cancer. 2002 Mar 20;98(3):362-9
pubmed: 11920587
J Biol Chem. 2003 May 16;278(20):18671-81
pubmed: 12637511
J Biol Chem. 2003 Oct 24;278(43):41881-9
pubmed: 12915404
Cell Death Differ. 1997 Dec;4(8):713-24
pubmed: 16465284
Biochem Biophys Res Commun. 2006 Dec 8;351(1):192-7
pubmed: 17055458
Cell. 2007 Jan 12;128(1):171-82
pubmed: 17218263
Mol Biol Cell. 2007 Apr;18(4):1233-41
pubmed: 17229885
J Biol Chem. 2007 Nov 30;282(48):34929-37
pubmed: 17901052
J Biol Chem. 2008 Jul 18;283(29):20350-60
pubmed: 18487611
Clin Cancer Res. 2008 Sep 1;14(17):5555-64
pubmed: 18765548
J Clin Oncol. 2009 Jan 10;27(2):289-97
pubmed: 19047291
Cancer Cell. 2009 Jan 6;15(1):67-78
pubmed: 19111882
J Clin Oncol. 2009 Mar 1;27(7):1007-13
pubmed: 19171716
J Biol Chem. 2009 Jul 24;284(30):19817-25
pubmed: 19460753
Oncogene. 2010 Mar 4;29(9):1249-59
pubmed: 20101214
Dev Neurobiol. 2011 Nov;71(11):901-23
pubmed: 21714101
Clin Cancer Res. 2011 Nov 1;17(21):6858-66
pubmed: 21908574
Nat Rev Cancer. 2013 Jun;13(6):397-411
pubmed: 23702928
Cold Spring Harb Perspect Med. 2013 Oct 01;3(10):a014415
pubmed: 24086065
J Dig Dis. 2014 Apr;15(4):159-65
pubmed: 24373518
J Biol Chem. 2014 Jun 20;289(25):17699-708
pubmed: 24808173
Int J Mol Sci. 2017 Jan 17;18(1):
pubmed: 28106752
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634
pubmed: 28652369
Paediatr Drugs. 2017 Dec;19(6):577-593
pubmed: 28786082
Jpn J Clin Oncol. 2018 Mar 1;48(3):214-241
pubmed: 29378002
Signal Transduct Target Ther. 2018 Feb 23;3:5
pubmed: 29527331
Children (Basel). 2018 Aug 06;5(8):null
pubmed: 30082653
Children (Basel). 2018 Aug 28;5(9):null
pubmed: 30154341
Blood. 1995 May 15;85(10):2643-53
pubmed: 7742522
J Biol Chem. 1996 May 10;271(19):11067-75
pubmed: 8626649
J Neurosci Res. 1997 Jul 1;49(1):53-63
pubmed: 9211989